Replies to post #102189 on Biotech Values

[DewDiligence]

Are you suggesting they should have moved to 2B with Ritonavir boosting?

ITMN’s guidance had been for phase-2b in genotype-1/4 patients to start in 4Q10 (http://finance.yahoo.com/news/InterMune-Reports-Second-prnews-111898175.html?x=0&.v=1 ):

A Phase-2b study of ritonavir-boosted danoprevir plus SOC is expected to begin in the fourth quarter of 2010; the exact timing will be determined with our collaboration partner Roche.

Given that Roche is conducting yet another small PK/safety study, the above timing now seems unlikely.